A New Era in Flu Prevention

The U.S. Food and Drug Administration has approved the first messenger RNA (mRNA) influenza vaccine for use in adults aged 18 and older during the 2026-2027 flu season. The approval marks a watershed moment in vaccine technology, extending the mRNA platform that proved transformative during the COVID-19 pandemic to the most common seasonal respiratory illness.

The vaccine, developed by Moderna under the brand name mRNA-1010, targets four influenza strains — two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata) — matching the quadrivalent composition recommended by the World Health Organization for the upcoming Northern Hemisphere season.

Clinical Trial Results

The approval was based on data from a Phase 3 clinical trial enrolling over 23,000 participants across 150 sites in North America and Europe. The key findings demonstrated clear advantages over traditional flu vaccines:

Why mRNA Changes the Game

Traditional influenza vaccines are primarily manufactured using chicken eggs, a process that takes approximately six months and can introduce mutations that reduce vaccine effectiveness. The egg-based manufacturing process also creates vulnerabilities in the supply chain and limits the speed at which vaccines can be updated to match circulating strains.

mRNA technology eliminates these constraints. The synthetic manufacturing process can produce vaccine candidates within weeks of strain identification, allowing for much closer matching to circulating viruses. This speed advantage also provides a hedge against pandemic influenza scenarios, where rapid vaccine production could save millions of lives.

"This approval represents the culmination of years of investment in mRNA technology. We believe it will fundamentally change how the world approaches seasonal influenza prevention." — Moderna CEO

Safety Profile

The safety data from clinical trials showed a side effect profile similar to existing mRNA vaccines. The most commonly reported adverse reactions included:

Most side effects were mild to moderate and resolved within 48 hours. No serious adverse events were attributed to the vaccine in the trial. The FDA will continue post-marketing surveillance through its established safety monitoring systems.

Manufacturing and Distribution

Moderna has indicated that it can produce up to 100 million doses for the U.S. market in the initial season, with plans to scale production significantly in subsequent years. The vaccine will be distributed through standard pharmacy and healthcare provider channels and is expected to be covered by most insurance plans under the Affordable Care Act's preventive services provisions.

The list price has been set at $95 per dose, comparable to existing premium flu vaccines such as Fluzone High-Dose and Flublok. The company has committed to providing doses at reduced cost through federal vaccine programs for uninsured populations.

Implications for Public Health

Influenza remains a significant public health burden in the United States, causing an estimated 12,000 to 52,000 deaths annually depending on the severity of the season. A more effective vaccine could substantially reduce these numbers, particularly among high-risk populations including the elderly, immunocompromised individuals, and young children.

The CDC's Advisory Committee on Immunization Practices (ACIP) is expected to issue recommendations on the use of mRNA-1010 alongside traditional flu vaccines at its June meeting. The upcoming flu season will provide the first large-scale real-world test of whether the clinical trial advantages translate into meaningful public health improvements.

What Comes Next

Moderna is also advancing combination mRNA vaccines that target both influenza and COVID-19 in a single injection. Phase 2 data for this combination vaccine are expected later in 2026. If successful, such a product could simplify seasonal vaccination campaigns and improve uptake by reducing the number of injections required.